Original scientific paper
https://doi.org/10.20471/may.2022.58.01.02
Effect of Atypical Antipsychotics on Serum BDNF in an Egyptian First Samples of First Episode Schizophrenia Patients
Reem Hassan Elghamry
; Okasha Institute of Psychiatry, Neuropsychiatry department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Ahmed Saad Mohammed
; Okasha Institute of Psychiatry, Neuropsychiatry department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Doa Mohammed Ali
; Okasha Institute of Psychiatry, Neuropsychiatry department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Yomna El Hawary
; Okasha Institute of Psychiatry, Neuropsychiatry department, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Abstract
Aim: The study is one of only few studies that was concerned with effect of atypical antipsychotics on serum Brain-Derived Neutorophic Factor (BDNF) level, as well as the relation between serum BDNF level and severity of symptoms. Methods: This was a prospective study conducted on 45 patients with first episode schizophrenia, patients were diagnosed by Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), severity of symptoms assessed by PANSS (Positive And Negative Syndrome) scale, serum level of BDNF was assessed in all patients before starting their medication and after 6 weeks of receiving atypical antipsychotic. Results: Serum BDNF levels were decreased after 6 weeks of treatment with atypical antipsychotic in patients with first episode schizophrenia, risperidone and quetiapine showed statistically significant decrease (p values 0.004, 0.041 respectively) in BDNF level after 6 weeks of therapy. PANSS score was decreased after 6 weeks of treatment with atypical antipsychotic in patients with first episode schizophrenia. Quetiapine showed the highest mean difference 65.4 ± 13.5 and the amisulpride showed the least mean difference 43.7 ± 4.9. There was no significant correlation between serum BDNF level and severity of the symptoms (p value 0.328), while we established a negative correlation between BDNF level and negative symptoms (r = -0.321). We did not establish significant differences (p value = 0.604) between subtypes of schizophrenia regarding BDNF level. Conclusions: Further cognitive, neuropsychological and psychopathological assessment could be useful to clarify the involvement of BDNF in the endophenotypic characteristics of schizophrenia.
Keywords
BDNF; first episode schizophrenia; atypical antipsychotic
Hrčak ID:
274124
URI
Publication date:
20.3.2022.
Visits: 1.212 *